Immunogen, Inc.

NASDAQ:IMGN   3:59:58 PM EDT
3.53
+0.02 (+0.57%)
Products, Other Pre-Announcement

Immunogen Submits Biologics License Application To The FDA For Mirvetuximab Soravtansine In Ovarian Cancer

Published: 03/29/2022 10:46 GMT
Immunogen, Inc. (IMGN) - Immunogen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer.
Immunogen Inc - Submission Based on Positive Results From Pivotal Phase 3 Soraya Trial.
Immunogen Inc - Continues to Enroll Patients in Confirmatory Mirasol Trial Designed to Generate Randomized Data Needed for Full Approval.
Immunogen Inc - Expects to Announce Top-line Data From Mirasol Trial in Q3 of 2022.
Immunogen Inc - Expects to Announce Top-line Data From Mirasol Trial in the Third Quarter of 2022.